

Cancer Drugs Fund notification numbers by drug and indication: reporting period Apr-16 to Mar-17

A. Summary

The Cancer Drugs Fund (CDF) is a source of funding for cancer drugs in England. On 29 July 2016, the approach to the appraisal and funding of cancer drugs in England was reformed and a new CDF introduced, which provides earlier access to cancer drugs than before. The NICE appraisal process starts much earlier, to enable final guidance to be published soon after a drug has received its license.

The information below sets out the number of patients notified to the CDF, broken down by month for each cancer treatment. Please note that notifications reflect the number of patients registered to receive treatment through the CDF: this may not represent the number of these patients who actually went on to receive treatment. Notifications to use drugs that have moved into routine commissioning are not reflected in the table below.

In the period Apr-16 to Mar-17 the CDF received:

10239	patient notifications for transition drugs ¹
3241	patient notifications for drugs receiving interim CDF funding ²
99	patient notifications for drugs receiving CDF funding via a managed access agreement ³
15	patient notifications received for drugs that have since been removed from the CDF
13594	patient notifications overall

Making a total of

Notes:

- 1 In 2016/17 the CDF was continuing to fund drugs from the old CDF (pre-July 2016) until they were re-appraised by the National Institute for Health and Care Excellence (NICE) or NHS England (in the case of the off-label drug indications).
- 2 All newly recommended cancer drugs receive interim CDF funding giving patients access to these treatments many months earlier than before.
- 3 CDF managed access agreements (MAA) provide funding for treatments that show clinical promise, but for which further data collection is needed in order to resolve uncertainty around their effectiveness.

B. Report by drug and indication*

Please note: where notification numbers are low and therefore risk potentially identifying patients, the monthly and annual figures have been suppressed.

Blueteq Form ref:	Drug	Indication	Apr-16	May-16	Jun-16	Jul-16	Aug-16	Sep-16	Oct-16	Nov-16	Dec-16	Jan-17	Feb-17	Mar-17	TOTAL 2016/17
AB11	Abiraterone	The treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	75	65	82	36	0	0	0	0	0	0	0	0	258
BEN1	Bendamustine	The first line treatment of low grade lymphoma	79	81	73	77	69	83	73	87	76	83	79	73	933
BEN2	Bendamustine	The first line treatment of mantle cell non-Hodgkin's lymphoma	11	10	<10	<10	<10	<10	12	12	13	11	10	11	123
BEN5	Bendamustine	The treatment of relapsed multiple myeloma	29	<10	19	18	15	16	21	10	<10	12	<10	14	179
BEN6	Bendamustine	The treatment of relapsed low grade lymphoma	42	41	57	47	45	46	38	40	27	40	37	47	507
BEV2	Bevacizumab	The first line treatment of recurrent or metastatic cervical cancer in combination with chemotherapy	17	16	14	10	15	16	13	17	13	16	13	18	178
BEV3	Bevacizumab	The first line treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer	71	72	62	88	73	63	70	87	71	71	58	79	865
BEV8	Bevacizumab	The third line treatment of low grade gliomas of childhood	0	<10	<10	0	<10	<10	<10	<10	0	<10	<10	0	<100
BOR1	Bortezomib	The treatment of bortezomib naive relapsed multiple myeloma	<10	<10	<10	<10	<10	<10	0	<10	<10	<10	<10	<10	<100
BO53	Bosutinib	Treatment of chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia in adults	<10	<10	<10	<10	<10	<10	17	12	0	0	0	0	<100
BRE1	Brentuximab	The treatment of relapsed or refractory systemic anaplastic large cell lymphoma in CHLD patients	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<50
BRE2	Brentuximab	The treatment of relapsed or refractory CD30+ Hodgkin's lymphoma	<10	16	17	17	12	15	8	16	14	18	19	18	179

Bluebird Form ref:	Drug	Indication	Apr-16	May-16	Jun-16	Jul-16	Aug-16	Sep-16	Oct-16	Nov-16	Dec-16	Jan-17	Feb-17	Mar-17	TOTAL 2016/17
CABA1	Cabazitaxel	The treatment of castrate-resistant Metastatic Prostate Cancer	41	48	35	0	0	0	0	0	0	0	0	0	124
CABO1	Cabozantinib	The first line treatment of medullary thyroid cancer	0	0	0	<10	<10	0	0	<10	0	<10	0	0	<100
CER1	Ceritinib	The treatment of anaplastic lymphomakinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer	0	0	0	0	12	<10	0	0	0	0	0	0	<100
CET1	Cetuximab	The treatment of previously untreated metastatic colorectal cancer in combination with irinotecan	91	85	107	101	99	105	102	120	84	101	87	95	1177
CET4	Cetuximab	The treatment of previously untreated metastatic colorectal cancer in combination with oxaliplatin	19	17	31	17	26	32	19	27	24	24	19	25	280
CET7	Cetuximab	The first line treatment of advanced head and neck cancer	30	18	25	15	27	17	26	32	20	31	19	39	299
CLO1	Clofarabine	The treatment of relapsed/refractory acute lymphoblastic leukaemia	<10	0	0	<10	<10	0	0	<10	0	<10	<10	<10	<100
CLO2	Clofarabine	The treatment of relapsed/refractory acute myeloblastic leukaemia	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<50
CR1	Crizotinib	The second and subsequent line treatment of ALK +ve advanced or metastatic non-small cell lung cancer	<10	<10	12	11	11	18	10	12	<10	<10	<10	<10	113
CR2	Crizotinib	The 1st line treatment of ALK +ve advanced or metastatic non-small cell lung cancer	0	0	0	0	<10	10	18	15	<10	0	0	0	<100
DAS1	Dasatinib	The treatment of previously treated accelerated phase chronic myeloid leukaemia	0	<10	<10	<10	<10	<10	<10	0	<10	0	<10	<10	<100
DAS3	Dasatinib	The treatment of previously treated chronic phase chronic myeloid leukaemia	<10	<10	13	<10	<10	<10	10	11	16	22	14	12	125
DAS6	Dasatinib	The treatment of untreated chronic phase chronic myeloid leukaemia	0	0	0	0	0	0	0	0	<10	<10	<10	0	<100
ENZ2	Enzalutamide	The treatment of chemotherapy naïve castrate-resistant Metastatic Prostate Cancer	173	<10	0	0	0	0	0	0	0	0	0	0	<200
ER1	Eribulin	The treatment of advanced breast cancer	83	83	85	97	71	84	66	73	53	0	0	0	695
EVE1	Everolimus	The treatment of advanced breast cancer	35	44	42	52	52	65	61	53	37	0	0	0	441
EVE3	Everolimus	The treatment of metastatic renal cell carcinoma	<10	0	<10	10	<10	<10	<10	<10	<10	<10	0	<10	<50
IBR1	Ibrutinib	The treatment of relapsed/ refractory Chronic Lymphocytic Leukaemia	44	38	57	57	47	34	57	55	47	75	67	87	665
IBR2	Ibrutinib	The treatment of relapsed/ refractory Mantle Cell Lymphoma	18	13	17	20	16	19	15	30	15	19	16	22	220
IBR3	Ibrutinib	The treatment of Chronic Lymphocytic Leukaemia with 17p deletion or TP53 mutation	0	0	0	0	0	0	0	0	<10	<10	16	21	<100
IPIN1	Ipilimumab and Nivolumab	The treatment of advanced (unresectable or metastatic) melanoma in adults	0	0	0	<10	37	29	31	0	0	0	0	0	<200
LEN1	Lenalidomide	The treatment of myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality	<10	<10	<10	<10	0	0	0	0	0	0	0	0	<100
NEL1	Nelarabine	The treatment of refractory T-cell acute lymphoblastic leukaemia or refractory T-cell lymphoblastic non-Hodgkin's lymphoma	<10	<10	<10	<10	<10	<10	<10	<10	<10	0	<10	<10	<50
NIV1	Nivolumab	The treatment of previously treated advanced renal cell carcinoma	0	0	0	0	0	0	38	103	59	0	0	0	200
OS1	Osimertinib	The treatment of locally advanced or metastatic epidermal growth factor receptor and T790M mutation-positive non-small-cell lung cancer (NSCLC)	0	0	0	0	0	0	10	18	16	23	13	19	<100
PAN1	Panitumumab	The treatment of previously untreated metastatic colorectal cancer in combination with oxaliplatin	16	22	23	18	23	24	15	18	17	23	24	20	243
PAN3	Panitumumab	The treatment of previously untreated metastatic colorectal cancer in combination with irinotecan	<10	12	16	<10	<10	10	15	16	16	24	12	24	163
PEM2	Pemetrexed	The maintenance treatment of advanced non-squamous non-small cell lung cancer	52	50	40	44	37	0	0	0	0	0	0	0	223
PEMB1	Pembrolizumab	The treatment of PD-L1-positive non-small-cell lung cancer after chemotherapy	0	0	0	0	0	0	0	0	71	166	67	0	304
PER1	Pertuzumab	The first line treatment of locally advanced or metastatic breast cancer	77	88	76	73	75	72	80	115	57	59	70	67	909
PER2	Pertuzumab	The neoadjuvant treatment of locally advanced, inflammatory or early breast cancer at high risk of recurrence	0	0	0	0	0	0	0	0	110	133	130	74	447
PLD1	Pegylated Liposomal Doxorubicin	The treatment of sarcomas	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<50
POM1	Pomalidomide	The treatment, with dexamethasone, of relapsed and refractory multiple myeloma after at least three regimens including lenalidomide and bortezomib	0	0	0	0	0	0	0	17	72	104	84	83	360
PON1	Ponatinib	The treatment of Philadelphia chromosome positive acute lymphoblastic leukaemia	<10	0	0	0	<10	0	<10	<10	<10	0	<10	<10	<50
PON2	Ponatinib	The treatment of Chronic Myeloid Leukaemia with T315I Mutation	0	<10	0	<10	<10	0	0	<10	<10	0	0	0	<100

Blueteq Form ref:	Drug	Indication	Apr-16	May-16	Jun-16	Jul-16	Aug-16	Sep-16	Oct-16	Nov-16	Dec-16	Jan-17	Feb-17	Mar-17	TOTAL 2016/17
PON3	Ponatinib	The treatment of chronic phase chronic myeloid leukaemia	0	0	0	0	0	0	0	0	0	0	0	<10	<100
PON4	Ponatinib	The treatment of accelerated phase or blast phase chronic myeloid leukaemia	0	0	0	0	0	0	0	0	0	0	<10	<10	<100
RADIU2	Radium-223 Dichloride	The treatment of castration-resistant prostate cancer patients with bone metastases	44	34	34	34	26	35	68	65	49	0	0	0	389
REG1	Regorafenib	The treatment of previously treated unresectable or metastatic gastrointestinal stromal tumours	<10	12	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<100
RUX1	Ruxolitinib	The treatment of symptomatic splenomegaly in primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis	32	30	<10	0	0	0	0	0	0	0	0	0	<100
SOR1	Sorafenib	The first line treatment of advanced hepatocellular carcinoma	36	33	43	49	50	48	46	47	55	42	53	57	559
SOR2	Sorafenib	The treatment of papillary or follicular thyroid cancer	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<100
SUN1	Sunitinib	The treatment of pancreatic neuroendocrine carcinomas	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<100
TALL	Talimogene Laherparepvec	The treatment of metastatic melanoma	0	0	0	0	0	<10	0	<10	0	0	0	0	<100
TEM1	Temsirolimus	The treatment of advanced renal cell carcinoma	<10	0	<10	0	<10	<10	0	0	0	0	0	0	<100
TRA1	Trastuzumab Emtansine (Kadcyla)	The treatment of HER2-positive locally advanced/ unresectable or metastatic (Stage IV) breast cancer	46	42	34	51	36	54	45	54	47	59	51	45	564
TRADAB1	Trametinib and Dabrafenib	The treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation	0	0	0	14	131	41	0	0	0	0	0	0	186
TRI1	Trifluridine and Tipiracil	The treatment of metastatic colorectal cancer	0	0	0	0	60	150	122	112	0	0	0	0	444
VAN1	Vandetanib	The first line treatment of medullary thyroid cancer	<10	<10	<10	<10	<10	0	<10	<10	<10	<10	<10	0	<50
VIS1	Vismodegib	The treatment of locally advanced or metastatic Basal Cell Carcinoma	<10	13	11	12	14	12	11	<10	14	20	<10	11	142
			1235	1032	1089	1026	1151	1161	1145	1326	1163	1231	1018	1017	13594